Marshall Urist Sells 9,098 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 9,098 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $55.18, for a total value of $502,027.64. Following the completion of the sale, the executive vice president directly owned 9,099 shares in the company, valued at approximately $502,082.82. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $52.75, for a total value of $721,831.00.
• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total value of $726,073.04.

Royalty Pharma Stock Up 0.8%

Shares of RPRX stock traded up $0.41 during mid-day trading on Thursday, reaching $54.69. 2,461,173 shares of the company’s stock traded hands, compared to its average volume of 3,711,937. The company’s 50-day moving average price is $52.54 and its 200-day moving average price is $46.42. The company has a market cap of $31.49 billion, a P/E ratio of 37.20, a P/E/G ratio of 1.52 and a beta of 0.43. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $56.50.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. On average, equities analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a dividend of $0.235 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Citigroup boosted their price target on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. UBS Group lifted their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. JPMorgan Chase & Co. boosted their target price on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $53.71.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. LM Advisors LLC bought a new position in shares of Royalty Pharma during the fourth quarter valued at $26,000. Lloyd Advisory Services LLC. purchased a new position in Royalty Pharma in the 4th quarter worth about $30,000. Private Trust Co. NA raised its position in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 288 shares during the last quarter. Blue Trust Inc. lifted its stake in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 437 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its stake in Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 446 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.